Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) EPS (Basic) (2016 - 2025)

Moleculin Biotech's EPS (Basic) history spans 10 years, with the latest figure at -$26.06 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$26.06 for Q4 2025, up 85.72% from a year ago — trailing twelve months through Dec 2025 was -$28.52 (up 84.94% YoY), and the annual figure for FY2025 was -$28.42, up 84.97%.
  • EPS (Basic) for Q4 2025 was -$26.06 at Moleculin Biotech, down from -$0.68 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.09 in Q4 2021 to a low of -$182.45 in Q4 2024.
  • The 5-year median for EPS (Basic) is -$1.52 (2024), against an average of -$12.44.
  • The sharpest move saw EPS (Basic) plummeted 15944.44% in 2022, then surged 85.72% in 2025.
  • Year by year, EPS (Basic) stood at -$0.09 in 2021, then plummeted by 15944.44% to -$14.44 in 2022, then skyrocketed by 64.47% to -$5.13 in 2023, then tumbled by 3456.53% to -$182.45 in 2024, then surged by 85.72% to -$26.06 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$26.06, -$0.68, and -$1.15 for Q4 2025, Q3 2025, and Q2 2025 respectively.